A man with decades of progressive muscle weakness from hyperkalemic periodic paralysis regained strength and mobility after starting semaglutide, suggesting GLP-1 drugs may directly benefit skeletal muscle.
Strength returned to levels not seen in decadesAfter starting semaglutide, a patient who couldn't rise from a chair without help regained functional strength and mobility that he had lost by age 30.
What the researchers found
A 48-year-old man with hyperkalemic periodic paralysis (hyperPP) caused by a SCN4A sodium channel mutation experienced dramatic reversal of chronic myopathy after starting semaglutide for weight loss. Before treatment, he could not rise from a chair without help and had a very slow gait. Over the following year, his strength and quality of life returned to levels he hadn't experienced in decades. Previous treatments with acetazolamide and diclofenamide had been ineffective. The authors propose semaglutide acts on skeletal muscle through both insulin-dependent and insulin-independent mechanisms.
Why it matters
This case report reveals an unexpected therapeutic application of semaglutide — reversing chronic muscle weakness in a genetic muscle disorder. HyperPP has limited treatment options, and existing drugs have had poor success. The finding that a GLP-1 peptide drug can directly improve skeletal muscle function suggests semaglutide may have important effects on muscle biology beyond its known metabolic benefits, potentially opening a new treatment avenue for muscle disorders.
The numbers in context
n=1 · 48-year-old male · SCN4A gene mutation at position 704 (Thr→Met) · symptoms since childhood · permanent weakness since age 30 · semaglutide initiated spring 2023 · strength improvement over 1 year · could not rise from chair before treatment
How the study worked
This is a single case report describing the clinical observation of muscle function improvement in a patient with genetically confirmed hyperkalemic periodic paralysis who started semaglutide for weight management. The improvement was assessed clinically through functional capacity (ability to rise from a chair, gait quality) and patient-reported quality of life.
Who was studied
48-year-old male with hyperkalemic periodic paralysis (SCN4A mutation) and obesity
What this study cannot tell us
As a single case report, causal attribution is uncertain — the improvement could potentially be related to weight loss effects or other factors rather than direct semaglutide effects on muscle. There is no controlled comparison or objective muscle testing data (e.g., electromyography, muscle biopsy, or quantitative strength measurements). The mechanism of action on skeletal muscle is proposed but not experimentally validated in this report.
How to read the evidence
This is a single case report (n=1), representing the lowest level of clinical evidence. While the dramatic clinical improvement is compelling, case reports cannot establish causation, and the finding needs to be replicated in larger studies before drawing conclusions.
When this study was published
Published in 2025, this case report reflects a very recent and novel observation about semaglutide's potential effects on skeletal muscle in a genetic muscle disorder.
The bigger picture
This serendipitous discovery adds to growing evidence that GLP-1 receptor agonists have important effects beyond metabolism and appetite. If semaglutide truly acts directly on skeletal muscle, it could have implications not just for hyperPP but for other muscle-wasting conditions, aging-related sarcopenia, and muscle disorders. It exemplifies how widely prescribed drugs can reveal unexpected therapeutic applications when clinicians observe carefully.
Questions still open
- Does semaglutide act directly on GLP-1 receptors in skeletal muscle, or is the benefit mediated through metabolic improvements?
- Could semaglutide benefit other forms of periodic paralysis or channelopathy-related muscle disorders?
- Would the muscle benefits of semaglutide be seen in other muscle-wasting conditions like sarcopenia or muscular dystrophies?
Common questions
What is hyperkalemic periodic paralysis and why is it hard to treat?
How might semaglutide help skeletal muscle?
Read the original research
Semaglutide reverses the chronic myopathy of hyperkalemic periodic paralysis: a case report.
BMC nephrology, 26(1), 179
Citation
Brand, Kenneth; Landry, Daniel; Mulhern, Jeffrey; Braden, Gregory. (2025). Semaglutide reverses the chronic myopathy of hyperkalemic periodic paralysis: a case report.. BMC nephrology, 26(1), 179. https://doi.org/10.1186/s12882-025-04068-5